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Introduction
The cryopyrin-associated periodic syndromes (CAPS) are
characterized by recurrent episodes of systemic inflamma-
tion. CAPS is caused by mutations in the NLRP3 gene
encoding cryopyrin, an important component of the
NLRP3 inflammasome that activates caspase-1 resulting in
inflammation by excessive production of IL-1b and others.
A diagnostic dilemma is often encountered in patients
with unspecific inflammatory symptoms like fatigue,
muscle pain, arthralgia or slight hearing loss and low
penetrance variants in NLRP3 / CIAS with an inconsistent
clinical phenotype. The analysis of IL-1b in the serum did
not prove to be a valid diagnostic test in these individuals.
Objectives
In this study we sought to investigate, if a functional
inflammasome activation assay discriminates between
genetically proven CAPS patients, patients with low
penetrance NLRP3 variants and healthy controls.
Methods
The study population consisted of 16 patients with
genetically proven Muckle-Wells syndrome, 9 patients
with low penetrance NLRP3 variants (V198M, Q703K
and E627G) and 14 healthy controls. Concentrations of
IL-1b, IL-1a, IL-18, and Caspase-1 were quantified in
cell culture supernatants after inflammasome stimula-
tion with LPS and LPS + ATP for several timepoints.
Results
After 4h of LPS stimulation, secretion of NLRP3 inflam-
masome products (IL-1b, IL-1a, IL-18) and Caspase-1
were potently increased in MWS patients, whereas there
was no increase in low penetrance NLRP3 variants and
healthy controls (for IL-1b p < 0.001 and p < 0.001,
respectively). Minor differences were still detected at
later timepoints and for LPS + ATP stimulation.
Conclusion
Our functional inflammasome activation assay discrimi-
nates between genetically proven CAPS patients and
patients with low penetrance NLRP3 variants. This assay
might add to the decision, which individuals presumably
benefit from an anti-IL-1 therapy.
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